An interventional study of EXOPULSE Mollii Suit Stimulation in Sclerosis, Multiple, MS (Multiple Sclerosis) and Spastic, sponsored by Sheikh Shakhbout Medical City. Recruiting at 1 site in United Arab Emirates. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-18.
Sponsored by Sheikh Shakhbout Medical City · Not applicable, Interventional, and Supportive care
The goal of this clinical trial is to demonstrate the improvement of muscular oxygenation in patients with Multiple Sclerosis and spasticity using Exopulse Molli suit stimulation. The main questions it aims to answer are:
Study subjects will participate in:
Researchers will compare both Active and Sham groups to demonstrate the improvement of muscular oxygenation in patients with MS and spasticity using Exopulse Molli.
The study is a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of "active" versus "sham" Exopulse Mollii suit separated by 2 weeks. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms.
704 studies on the registry are indexed under Muscle Spasticity; 149 are open to participants now.
This study's planned enrollment of 36 is close to the median of 36 across 525 interventional studies indexed under Muscle Spasticity.
Browse Muscle Spasticity studies →Sheikh Shakhbout Medical City is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes.
Device: EXOPULSE Mollii Suit Stimulation
This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes.
Device: EXOPULSE Mollii Suit Stimulation
We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of "active" versus "sham" Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms.
Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements
Muscular Oxygenation will be assessed using the Near-infrared spectroscopy (NIRS) technology using a PortaMon device it will be employed to assess tissue oxygenation parameter (hemoglobin (tHb) in the territory of the spastic muscles before and after each session.
Time frame: To be assessed at baseline, week 2, week 4 and week 8
Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements
Muscular Oxygenation will be assessed using the Near-infrared spectroscopy (NIRS) technology using a PortaMon device it will be employed to assess tissue oxygenation parameter oxyhemoglobin (O2Hb) in the territory of the spastic muscles before and after each session.
Time frame: To be assessed at baseline, week 2, week 4 and week 8
Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements
Muscular Oxygenation will be assessed using the Near-infrared spectroscopy (NIRS) technology using a PortaMon device it will be employed to assess tissue oxygenation parameter deoxyhemoglobin (HHb) in the territory of the spastic muscles before and after each session.
Time frame: To be assessed at baseline, week 2, week 4 and week 8
Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements
Muscular Oxygenation will be assessed using the Near-infrared spectroscopy (NIRS) technology using a PortaMon device it will be employed to assess tissue oxygenation parameter tissue oxygenation index (TOI%)) in the territory of the spastic muscles before and after each session.
Time frame: To be assessed at baseline, week 2, week 4 and week 8
Numerical Rating Scale for spasticity.
Spasticity will be evaluated using a Numerical Rating Scale (NRS) score from 0 to 10, 0 being no spasticity and 10 being the worst possible spasticity.
Time frame: This to be assessed at baseline, then at week 2, week 4 and week 8.
Multiple Sclerosis International Quality of Life Questionnaire.
Quality of life will be measured using the 31-item Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) This questionnaire consists of 31 questions covering 9 domains including: 1- activity of daily living, 2- physical well-being, 3- relationships with friends, 4- symptoms, 5- relationships with family; 6- relationships with health care systems, 7- sentimental and sexual life, 8- coping; and 9- rejection. The questions are answered by ticking or checking the box that describes best of what patients would feel ranging from 0 to 4, 0 being not at all and 4 always or very much. For MusiQoL, the score of each of the nine sub domains is calculated as the average for the set of questions making up the domain. An overall score is then calculated as the average of all the scores for each subdomain. Prior to computing the final overall score, each domain-specific score is linearly transformed to a 0-100 scale with O being the worst quality of life and 100 the best.
Time frame: Two weeks after the second stimulation and 4 weeks later at the end of phase 2.
Visual Analog Score for pain.
Pain will be measured using a visual analog score from 0 to 10, 0 being no pain, to 10 being the worst possible pain.
Time frame: This to be assessed at baseline, then at week 2, week 4 and week 8.
Visual Analog Score for fatigue.
Fatigue will be measured using a visual analog score from 0 to 10, 0 being no fatigue, to 10 being the worst possible fatigue.
Time frame: This to be assessed at baseline, then at week 2, week 4 and week 8.
Fall risk.
Fall risk will be assessed using the Falls Efficacy Scale- International scale. It is a 16-item scale, including a range of functional activities, that assesses the perceived risk of falling, using a score that will range from 1 to 4, 1 being not at all concerned to 4 being very concerned.
Time frame: Two weeks after the second stimulation and at the end of phase 2.
Walking ability.
Walking ability will be evaluated by the 12-item Multiple Sclerosis Walking Scale (MSWS-12). Each one of the 12 items will be assessed and assigned numbers from 1 to 5, 1 being not at all to 5 being extremely common, and the results will be added to a total of 60, so the higher the score, the better the mobility.
Time frame: Two weeks after the second stimulation and at the end of phase 2.
Overall Clinical Improvement.
Evaluation of overall Clinical improvement will be done using the 7-point Clinical Global Impression (CGI). Patient will fill a questionnaire that will address their clinical situation as follows: 1. Very much improved. 2. Much improved. 3. Slightly improved. 4. No change. 5. Slightly worse 6. Much worse. 7. Very much worse The score will range from 1-7, 1 being the best clinical outcome and 7 the worst.
Time frame: This to be assessed at baseline, then at week 2, and week 8.
Blinding Questionnaire.
Evaluation of patient's blinding to the type of stimulation in the crossover trial periods using a dedicated questionnaire. Patients will be asked whether they think they received the sham or active stimulation. No scale will be used for this measure.
Time frame: This to be assessed at baseline, then at week 2.
Weight
The patient weight will be measured and recorded in kilograms.
Time frame: Baseline.
Height
The patient height will be measured and recorded in centimeters.
Time frame: Baseline.
Muscle tone.
Muscle tone will be evaluated by the Modified Ashworth Scale (MAS). Scores will range from 0 to 4, 0 being no increase or normal muscle tone, to 4 being rigidity in flexion or extension of muscles.
Time frame: Baseline, and through study completion.
Body Mass Index (BMI)
The weight and height will be combined to report BMI in kg/m\^2. BMI of 35 kg/m\^2 or more will be used as an exclusion criterion for the study.
Time frame: Baseline.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sheikh Shakhbout Medical City